Yesssss!!...Word on MSTX is starting to get around louder and louder. Watch for a significant breakout any day now
No wonder the 5 analysts price MSTX at $2.8/share and some at $5~!!
2 to 3M potential American patients/clients and about 20 more million globally!!!!
They know that Phase 3 results will be good
At same time Sushil and other insiders were loading up. Just becoming more efficient and possibly putting some lipstick for a potential sale of the company to a larger entity (FLEX, SANM)
Get in now....warrants completed exercising at end of December.....No overhang now.
All three picks are starting to move up
Tax selling ends tomorrow and January effect will start on Monday......interim catalysts until blockbuster news releases in 1Q 2016
Another 40c company with huge upside is STRI.
STRI already has 60c/share cash and no debt. Will have $3/share cash no debt after $10M land sale in Malaysia and $8M tax credit as well as almost $4M in other cash proceeds.
STRI announced in 3Q 2015 earnings that demand for its products has skyrocketed in 4Q and its majority owner ( major Chinese solar power supplier Zhenfa 51% owner) is building 2 plants to keep up with product demand. Revenues will increase from $6M/quarter to over $20M/quarter....Market cap is only $7M ad tiny float.
STRI will reach $5+ in 2016 and will move from OTCBB to NASDAQ
My target is $8 at the end of 2016
Buying with both hands ate these prices.
Tax sell-off will be over soon followed by the January Effect....$$$$
Dr. Kanak Kanti De: Is Jack Lief still involved with Mast? If not, why not?
Brian Culley: Mr. Lief left our Board of Directors in early August. He made this decision to avoid any potential conflict of interest given his role at the time as President and CEO of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) and Arena's development of a product candidate for the treatment of pulmonary arterial hypertension (PAH). As a reminder, Mast's AIR001 had been tested in Phase 1 and 2 clinical studies for the treatment of PAH.
Great buy at these levels.
Like you said with a third consecutive quarter coming up and to be reported in about 6 more weeks, low float and the January Effect, FORD might be headed to $5++ in 2016
Excerpts of Maxim research note:
Mast's vepoloxamer is now in a pivotal phase III (EPIC) study. Data for the treatment of pain crises in sickle cell disease (SCD) is expected by 1Q16. If positive and pending approval, vepoloxamer could be on the market by 2017 in the U.S. and 2018 in Europe.
How big is the opportunity? Vepoloxamer would be the second drug approved for sickle cell disease — and the only drug approved for treating crises directly. Sweetening the opportunity is the fact that the 100,000 annual sickle cell hospitalizations in the U.S. for pain crises take place in fewer than 200 hospitals, meaning the launch trajectory could be steep.
Mast is a value play for investors, in our opinion. What we believe to be due to a prior phase III failure, Mast’s valuation is distressed. However, lessons learned have helped Mast design the ongoing EPIC study to be better powered and to have the right endpoint and the right patients. Thus, the probability of success has been optimized, in our view. Additionally, the excitement of gene therapy in SCD is overshadowing what appears to be a critical and important new viable therapeutic option for patients.
Mast is a phase 3 company, with a sub $100M market cap and $45M in cash with data expected in 1Q16. Given the design of the EPIC study (built on the shoulders of the prior study) of vepoloxamer we believe the probability of success is high. Mast could have the first SCD drug to treat pain crises.
My target is $8/share by the end of 206 as vepo starts demonstrating a lot of benefits outside of SCD
I am adding more on Monday and holding for 2 to 3 years